AstraZeneca Pharma [ASTRAZEN] vs Cipla [CIPLA] Detailed Stock Comparison

AstraZeneca Pharma

NSE

Cipla

NSE

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: AstraZeneca Pharma wins in 3 metrics, Cipla wins in 17 metrics, with 0 ties. Cipla appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	AstraZeneca Pharma	Cipla	Better
P/E Ratio (TTM)	188.67	22.27	Cipla
Price-to-Book Ratio	28.51	3.85	Cipla
Debt-to-Equity Ratio	4.64	1.40	Cipla
PEG Ratio	-6.66	23.38	AstraZeneca Pharma
EV/EBITDA	86.38	15.50	Cipla
Profit Margin (TTM)	6.74%	19.62%	Cipla
Operating Margin (TTM)	14.47%	22.31%	Cipla
EBITDA Margin (TTM)	14.47%	22.31%	Cipla
Return on Equity	15.62%	16.85%	Cipla
Return on Assets (TTM)	10.34%	14.10%	Cipla
Free Cash Flow (TTM)	$636.10M	$34.57B	Cipla
Dividend Yield	0.34%	1.72%	Cipla
1-Year Return	31.01%	3.22%	AstraZeneca Pharma
Price-to-Sales Ratio (TTM)	12.80	4.37	Cipla
Enterprise Value	$214.61B	$1,099.34B	Cipla
EV/Revenue Ratio	12.50	4.00	Cipla
Gross Profit Margin (TTM)	45.97%	68.25%	Cipla
Revenue per Share (TTM)	$687	$340	AstraZeneca Pharma
Earnings per Share (Diluted)	$46.56	$66.71	Cipla
Beta (Stock Volatility)	0.13	0.10	Cipla

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

AstraZeneca Pharma vs Cipla Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
AstraZeneca Pharma	0.70%	-1.23%	-3.75%	7.35%	16.40%	22.08%
Cipla	-0.27%	-1.13%	-0.17%	-0.07%	1.85%	0.43%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
AstraZeneca Pharma	31.01%	186.16%	164.33%	654.46%	622.38%	2,376.95%
Cipla	3.22%	44.65%	92.51%	100.89%	371.91%	976.20%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

AstraZeneca Pharma (ASTRAZEN): View Full Stock Overview

Cipla (CIPLA): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: AstraZeneca Pharma vs Cipla

Metric	ASTRAZEN	CIPLA
Market Information
Market Cap i	₹219.61B	₹1.20T
Market Cap Category	Large cap	Large cap
10 Day Avg. Volume i	15,844	1,677,051
90 Day Avg. Volume i	31,126	1,586,403
Last Close	₹8,784.50	₹1,485.00
52 Week Range	₹6,220.00 - ₹10,691.00	₹1,335.00 - ₹1,579.90
% from 52W High	-17.83%	-6.01%
All-Time High	₹10,691.00 (Jun 13, 2025)	₹1,577.00 (Jul 28, 2025)
% from All-Time High	-17.83%	-5.83%
Growth Metrics
Quarterly Revenue Growth	0.25%	0.03%
Quarterly Earnings Growth	0.48%	0.10%
Financial Health
Profit Margin (TTM) i	0.07%	0.20%
Operating Margin (TTM) i	0.14%	0.22%
Return on Equity (TTM) i	0.16%	0.17%
Debt to Equity (MRQ) i	4.64	1.40
Cash & Liquidity
Book Value per Share (MRQ)	₹308.14	₹386.24
Cash per Share (MRQ)	₹214.46	₹131.44
Operating Cash Flow (TTM) i	₹653.60M	₹55.16B
Levered Free Cash Flow (TTM) i	₹1.39B	₹52.73B
Dividends
Last 12-Month Dividend Yield i	0.34%	1.72%
Last 12-Month Dividend i	₹32.00	₹26.00

Valuation & Enterprise Metrics Analysis: AstraZeneca Pharma vs Cipla

Metric	ASTRAZEN	CIPLA
Price Ratios
P/E Ratio (TTM) i	188.67	22.27
Forward P/E i	N/A	23.38
PEG Ratio i	-6.66	23.38
Price to Sales (TTM) i	12.80	4.37
Price to Book (MRQ) i	28.51	3.85
Market Capitalization
Market Capitalization i	₹219.61B	₹1.20T
Enterprise Value i	₹214.61B	₹1.10T
Enterprise Value Metrics
Enterprise to Revenue i	12.50	4.00
Enterprise to EBITDA i	86.38	15.50
Risk & Other Metrics
Beta i	0.13	0.10
Book Value per Share (MRQ) i	₹308.14	₹386.24

Financial Statements Comparison: AstraZeneca Pharma vs Cipla

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	ASTRAZEN	CIPLA
Revenue/Sales i	₹4.80B	₹68.37B
Cost of Goods Sold i	₹2.60B	₹21.71B
Gross Profit i	₹2.21B	₹46.66B
Research & Development i	N/A	N/A
Operating Income (EBIT) i	₹686.80M	₹15.25B
EBITDA i	₹1.03B	₹20.37B
Pre-Tax Income i	₹784.70M	₹17.70B
Income Tax i	₹202.20M	₹4.78B
Net Income (Profit) i	₹582.50M	₹12.92B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	ASTRAZEN	CIPLA
Cash & Equivalents i	₹5.36B	₹5.89B
Total Current Assets i	₹13.42B	₹232.89B
Total Current Liabilities i	₹7.03B	₹54.84B
Long-Term Debt i	₹294.50M	₹2.52B
Total Shareholders Equity i	₹7.70B	₹312.89B
Retained Earnings i	N/A	₹256.44B
Property, Plant & Equipment i	₹635.80M	₹52.62B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	ASTRAZEN	CIPLA
Operating Cash Flow i	N/A	N/A
Capital Expenditures i	N/A	N/A
Free Cash Flow i	N/A	N/A
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	ASTRAZEN	CIPLA
Shares Short i	N/A	N/A
Short Ratio i	N/A	N/A
Short % of Float i	N/A	N/A
Average Daily Volume (10 Day) i	15,844	1,677,051
Average Daily Volume (90 Day) i	31,126	1,586,403
Shares Outstanding i	25.00M	807.62M
Float Shares i	4.14M	562.88M
% Held by Insiders i	0.82%	0.31%
% Held by Institutions i	0.06%	0.38%

Dividend Analysis & Yield Comparison: AstraZeneca Pharma vs Cipla

Metric	ASTRAZEN	CIPLA
Last 12-Month Dividend i	₹32.00	₹26.00
Last 12-Month Dividend Yield i	0.34%	1.72%
3-Year Avg Annual Dividend i	₹24.00	₹16.00
3-Year Avg Dividend Yield i	0.37%	0.76%
3-Year Total Dividends i	₹72.00	₹48.00
Ex-Dividend Date	Jul 18, 2025	Jun 27, 2025

AstraZeneca Pharma [ASTRAZEN] vs Cipla [CIPLA] Detailed Stock Comparison